The new dosing schedule with a more gradual titration significantly lowered incidence of ARIA-E in the TRAILBLAZER-ALZ 6 trial.

A journey through the FDA’s newly released complete response letters gave glimpses into the journeys to market for Eli ...

The health ministry is expected to cut the official price of the drug by up to 15% from the current level of about ¥3 million ...

A slower ramp-up of Kisunla dosing lowers the rate of dangerous brain swelling, a risk that has made doctors reluctant to ...

Eli Lilly has won a green light from the FDA for new dosing for its Alzheimer's disease therapy Kisunla, which carries a reduced risk of adverse reactions that may have held back its uptake in the ...

The FDA will allow a new dosing schedule for Eli Lilly’s Alzheimer’s drug Kisunla that could lessen a known side effect of ...

HATFIELD, HERTFORDSHIRE, UNITED KINGDOM (UK), and MAIDENHEAD, UK, 7 JULY 2025 – Eisai Europe Ltd. and Biogen Idec Ltd. announced today that the Scottish Medicines Consortium (SMC) has not recommended ...

DelveInsight's Frontotemporal Dementia Market Insights report includes a comprehensive understanding of current treatment ...

INmune Bio said that a subset of Alzheimer's disease patients in the study showed clinical benefit from the therapy.

By Siddhi Mahatole and Puyaan Singh (Reuters) -INmune Bio said on Monday its experimental Alzheimer's drug failed to improve cognitive functions in patients with early stages of the mind-robbing ...

(Reuters) -INmune Bio said on Monday its experimental Alzheimer's drug failed to improve cognitive functions in patients with ...

Eisai leads lecanemab’s development and regulatory submissions globally. Biogen and Eisai co-commercialize and co-promote the product. Eisai has final decision-making authority.